muscle the and showing as a structure skeletal improvements towards thank two clinical time CAP-XXXX for from joining afternoon, basic quarter we the function We to us cardiac improvements been to as now in for same results, This for you DMD. move has busy data Good update us, and for potential trials well our in call. function. have third continue registration as path
you on seven we know, ago. DMD As about working of many years started
that self and itself. muscular in studies mechanism our that published colleagues We have papers for we We have CAP-XXXX, and on XX our action two First the we not immunomodulatory the showing have – Duchenne are we the we the are dystrophy create of pathways, now which culminating directly mediating only seeing to trials. four the to the responsible on exosomes, of mouse repair peer in deeper CDCs, for believe reviewed therapy which drill muscle find elucidated foundation that the over and clinical we now with do but mdx and believe cells believe of the biological microRNAs, also be meeting the the the in cells clinic. effects
struggling advocacy that importance. strategically privacy. be one’s functioning the young is Duchenne, Dystrophy, able no Project lead and the largest We retain to no us carefully life as but built by a challenging of The CAP-XXXX peers Pat Parent arms the ability of of in Furlong, as reminds is longer for Muscular a to become are as potential desire and the same things as those have who around to DMD leader used are their therapeutic the impacted use their do. hands even organization who program boys greater retain when one walk. longer have independence ambulatory, to those men most and and are to a These
use have our our are later if is gene with eat, patients. hands. hair for We line We later few only We bottom comb and too hands arm. the of late and our these with eligible hug the brush treatment options not our our computers The that we because for therapies the may are muscle available stages arms. for they in use teeth phones can salvaging and and stage be furthermore it currently of of terms our the disease those in
the of is with living their be may are notable necessary muscular toolbox due what a to half battle in will be that others We lifespans therefore positioned It the Duchenne of treatment that currently are as CAP-XXXX increasing is is believe dystrophy. and use ideally that the eligible important primarily and DMD to that CAP-XXXX. for even potentially steroids. non-ambulant more But patients over
for the need the these later year result stage for a they therapies also will and which patients need in the treatments increasing. as So are
XXXX the International Muscle XX We with which October End-of-Phase latest FDA results Xth. pre-specified in also data on which presented the in Type We the World the at part the of was HOPE-X patients. six meeting That on included analysis of to Society recently Congress discuss Copenhagen met a Capricor call show cohort month the was shown FDA the in interim trial. the large of completion the B clinical on of a data, webinar the
The primary often the known data the original of well the mid was and which limb, the the with HOPE-X across that subgroups upper mid which CAP-XXXX granular entire patients level of treated in PUL, improvements as performance even as plus endpoint level, distal had PUL, which the and as the the hand, includes is both is the the at showed the efficacy the arm, clinical PUL of trial. shoulder, board, distal which of the level mid in
recommendation We PUL on show measurement HOPE-X true a of powerful fact also data. was tool the X.X the as more based FDA the version in that their
of accompanying also limb Furlong PI, performance meeting of with is measure the Craig the to CAP-XXXX. support and national International, co-creator us Our and Dr. the Atom a McDonald, FDA provided for Michelle PPMD, who of of significant upper the Pat Eagle
the at Phase book III becomes FDA a supportive patients. had of an continue for FDA trials, approval. is This the as of XX we FDA treatment During for for Prior provide of to we was however we to the to indicated possibility to briefing intend up withstanding, trial accelerated the not the calls protocols this meeting data trial the supportive DMD. discussion. the to Phase which in III draft of submitted our approval The did The CAP-XXXX propose available pathway accelerated meeting, this it time. not from HOPE-X additional a
on be to well plans CAP-XXXX guidance as developments FDA other with the clinical factors. the of received from further Our respect as DMD, the final in based will
anticipating the end. minutes meeting from are We before final year
closely designation, were therapy. the willing part they to the of reiterated to the our development addition, of In work with clinical FDA that us RMAT further as
we support the it second the HOPE-X presenting months positive we saw that the and the will from study are months. in hopeful of quarter Finally, results anticipate data XX six XXXX, that at we
that However, the to expect after several infusion infusions in be to that the it or voluntary we involuntary regimen. a lifted XXXX, resulted full we do not which missed dataset due was hold a subsequently late pre-medication from delayed occurred – instituted
technology field be remain CAP-XXXX at numerous symposia. biotechnology and quarter, antibodies. and committed In and remained development conferences on We potentially is that we believe medical in in a access this exosomes therapeutic an of program to grow. third that as them have will continuing someday attended the exciting relevant agent the on and the to as we exosomes the front, powerful preclinical continue be Lastly, to to engaged as presented
Our discussing collaboration with in the data interesting that XXXX. U.S. positive we Army forward generate continues to and and look to
Finally, into our XXXX. is goals hopefully to able one them of be to in the clinic bring
AJ the on That’s to all call I financials. update our Bergmann, over CFO our for will you to now. turn
